1,4-萘醌支架衍生的化合物已显示出相当大的抗癌药理特性,包括急性髓细胞性白血病(AML)其在AML中的影响和机制尚不确定。在这项研究中,通过网络药理学研究了1,4-萘醌支架衍生化合物抗AML的机制,分子对接和分子动力学模拟。ASINEX数据库用于收集1,4-萘醌支架衍生的化合物,和从软件中提取化合物,以评估它们的药物相似性和毒性。从SwissTargetPrediction数据库和相似性集成方法数据库中检索了化合物的潜在靶标,而AML的潜在靶标是从GeneCards数据库和基因表达Omnibus获得的。STRING数据库用于构建蛋白质-蛋白质相互作用(PPI)网络,从拓扑上讲,Cytoscape的CytoHubb插件会筛选中心目标。选择潜在的关键目标后,对交叉靶标进行了基因本体论(GO)功能注释和京都基因和基因组百科全书(KEGG)途径富集分析,并构建了“化合物-潜在靶标-途径-疾病”的网络图。进行了化合物与核心靶标的分子对接,选择结合力最强的核心靶标和1,4-萘醌支架衍生化合物进行进一步的分子动力学模拟和进一步的分子力学/泊松-玻尔兹曼表面积(MM/PBSA)方法验证。此外,应用Bloodspot数据库对核心目标进行总体生存.共筛选出19个1,4-萘醌支架衍生化合物,然后是836个目标化合物,筛选了96个AML的交叉靶标。核心目标包括STAT3、TLR4、HSP90AA1、JUN、MMP9,PTPRC,JAK2、PTGS2、KIT和CSF1R。GO功能富集分析表明,90个生物过程,富集了10种细胞成分和12种分子功能,而KEGG途径富集分析揭示了34种富集的信号通路。对KEGG富集的分析表明,这10个核心基因位于癌症的通路中,提示1,4-萘醌支架衍生化合物具有抗AML的潜在活性。分子对接分析表明,1,4-萘醌支架衍生化合物与核心蛋白之间的结合能均高于-6kcal/mol,表明10个核心靶标均与化合物具有较强的结合能力。此外,从化合物7和MMP9之间的分子动力学模拟推断良好的结合能力。使用MM/GBSA方法计算的总结合自由能显示MMP9-7复合物的值为-6356.865kcal/mol。此外,血点数据库结果显示HSP90AA1、MMP9和PTPRC与总生存期相关。这些发现为未来研究化合物与基于1,4-萘醌的支架结构的抗AML潜力的相互作用提供了基础。具有基于1,4-萘醌的支架结构的化合物在通过多个靶标和途径缓解和治疗AML中表现出相当大的潜力。
1,4-Naphthoquinone scaffold-derived compounds has shown considerable pharmacological properties against cancer, including acute myeloid leukemia (AML) However, its impact and mechanisms in AML are uncertain. In this study, the mechanisms of 1,4-naphthoquinone scaffold-derived compounds against AML were investigated via network pharmacology, molecular docking and molecular dynamics simulation. ASINEX database was used to collect the 1,4-naphthoquinone scaffold-derived compounds, and compounds were extracted from the software to evaluate their drug similarity and toxicity. The potential targets of compounds were retrieved from the SwissTargetPrediction Database and the Similarity Ensemble Approach Database, while the potential targets of AML were obtained from the GeneCards databases and Gene Expression Omnibus. The STRING database was used to construct a protein-protein interaction (PPI) network, topologically and Cyto Hubb plugin of Cytoscape screen the central targets. After selecting the potential key targets, the gene ontology (GO) function annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed for the intersection targets, and a network map of \"compounds-potential targets-pathway-disease\" were constructed. Molecular docking of the compounds with the core target was performed, and core target with the strongest binding force and 1,4-naphthoquinone scaffold-derived compounds was selected for further molecular dynamics simulation and further molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) approach verification. In addition, the Bloodspot database was applied to perform the overall survival of core targets. A total of 19 1,4-naphthoquinone scaffold-derived compounds were chosen out, and then 836 targets of compounds, 96 intersection targets of AML were screened. Core targets include STAT3, TLR4, HSP90AA1, JUN, MMP9, PTPRC, JAK2, PTGS2, KIT and CSF1R. GO functional enrichment analysis revealed that 90 biological processes, 10 cell components and 12 molecular functions were enriched while KEGG pathway enrichment analysis revealed 34 enriched signaling pathways. Analysis of KEGG enrichment hinted that these 10 core genes were located in the pathways in cancer, suggesting that 1,4-naphthoquinone scaffold-derived compounds had potential activity against AML. Molecular docking analysis revealed that the binding energies between 1,4-naphthoquinone scaffold-derived compounds and the core proteins were all higher than - 6 kcal/mol, indicating that the 10 core targets all had strong binding ability with compounds. Moreover, a good binding capacity was inferred from molecular dynamics simulations between compound 7 and MMP9. The total binding free energy calculated using the MM/GBSA approach revealed values of - 6356.865 kcal/mol for the MMP9-7 complex. In addition, Bloodspot database results exhibited that HSP90AA1, MMP9 and PTPRC were associated with overall survival. The findings provide foundations for future studies into the interaction underlying the anti-AML potential of compounds with 1,4-naphthoquinone-based scaffold structures. Compounds with 1,4-naphthoquinone-based scaffold structures exhibits considerable potential in mitigating and treating AML through multiple targets and pathways.